Format

Send to

Choose Destination
J Infect Dis. 2018 Aug 24;218(7):1147-1154. doi: 10.1093/infdis/jiy286.

Novel Treatment of Cryptococcal Meningitis via Neurapheresis Therapy.

Author information

1
Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
2
Department of Medicine, Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina.
3
Department of Anesthesiology, Duke University Medical Center, Durham, North Carolina.
4
Minnetronix, Inc, Saint Paul, Minnesota.

Abstract

Cryptococcal meningitis (CM) has emerged as the most common life-threatening fungal meningitis worldwide. Current management involves a sequential, longitudinal regimen of antifungals; despite a significant improvement in survival compared with uniform mortality without treatment, this drug paradigm has not led to a consistent cure. Neurapheresis therapy, extracorporeal filtration of yeasts from cerebrospinal fluid (CSF) in infected hosts, is presented here as a novel, one-time therapy for CM. In vitro filtration of CSF through this platform yielded a 5-log reduction in concentration of the yeast and a 1-log reduction in its polysaccharide antigen over 24 hours. Additionally, an analogous closed-loop system achieved 97% clearance of yeasts from the subarachnoid space in a rabbit model over 4-6 hours. This is the first publication demonstrating the direct ability to rapidly clear, both in vitro and in vivo, the otherwise slowly removed fungal pathogen that directly contributes to the morbidity and mortality seen in CM.

PMID:
29788431
PMCID:
PMC6107745
DOI:
10.1093/infdis/jiy286
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center